跳至主要内容
临床试验/NCT01834508
NCT01834508Unknown4 期

A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study

Nanfang Hospital, Southern Medical University28 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
600
试验地点
28
主要终点
Percentages of patients achieving HBV DNA< 300copies/mL at week 144

研究概览

简要总结

The purpose of this study is to evaluate the long-term efficacy and safety of entecavir 0.5 mg/d + adefovir 10 mg/d for treatment experienced chronic hepatitis B patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who completed the EXPLORE or EXCEL studies, or subjects with hepatitis flare after treatment withdrawal in EFFORT study.
  • Subjects who are willing to participate the extension study.

排除标准

  • Subjects who could not compliance with the protocol judged by investigators

研究组 & 干预措施

Treatment group

Other

干预措施: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks (Drug)

结局指标

主要结局

Percentages of patients achieving HBV DNA< 300copies/mL at week 144

时间窗: Week 144

次要结局

  • The log10 reduction in HBV DNA from baseline of DRAGON study at week 48/96/144(Week 48 & 96 &144)
  • Percentage of patients with HBeAg loss or HBeAg seroconversion at week 48/96/144.(Week 48 & 96 & 144)
  • Percentage of patients with ALT normalization at week 48/96/144(Week 48 & 96 & 144)
  • Percentages of patients achieving HBV DNA <300copies/mL at week 48/96(Week 48 & 96)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验

3E Extension Study | 临床试验